Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-05-21 23:18:48 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.9001
文献链接: https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9001
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Yi-Long Wu; Qing Zhou; Jie Wang; Yan Yu; Ligang Xing; Ying Wang; Ying Cheng; Yueyin Pan; Yun Fan; Jianhua Shi; Guojun Zhang; Jiuwei Cui; Jianying Zhou; Yong Song; Wu Zhuang; Zhiyong Ma; Yanping Hu; Gaofeng Li; Xiaorong Dong; Myung-Ju Ahn
